Wordt geladen...
Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival
A number of previous studies have reported that 30–50% of patients with colorectal cancer (CRC) harbor Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations, which is a major predictive biomarker of resistance to epidermal growth factor (EGFR)-targeted therapy. Treatment with an anti-EGFR inhi...
Bewaard in:
| Gepubliceerd in: | Mol Clin Oncol |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
D.A. Spandidos
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4534836/ https://ncbi.nlm.nih.gov/pubmed/26623049 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2015.602 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|